MAPT and Alzheimer disease: Our model behavior shows good agreement (R2 ≥ 0.4) with in vivo models of tauopathic disease at the regional level: for both AD-like and non-AD-like mouse models, we can parameterize our transport feedback model to produce biases in somatodendritic tau deposition that match the longitudinal trends in network spread bias (Fig 6 and S7 Fig) [20].